• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
Shop

American Psychedelic Practitioners Association (APPA) Launches Non-Profit

Microdose by Microdose
October 11, 2022
in Industry
Reading Time: 3 mins read
A A
American Psychedelic Practitioners Association (APPA) Launches Non-Profit

As psychedelic-assisted therapy moves its way through clinical trials and further into mainstream medical acceptance, standardizing practices for treatments and practitioners will be a crucial step in the sector’s development.

To this end, the American Psychedelic Practitioners Association (APPA) has announced the launch of their organization, establishing safe, ethical and accessible psychedelic therapy and specific focus Psychedelic Assisted Therapy (PAT).

See the full press release below.

 

[bsa_pro_ad_space id=2]
ADVERTISEMENT

 

Continue on your trip...

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

 

PRACTITIONERS CALL FOR PSYCHEDELIC SPACE OPERATING STANDARDS

 

American Psychedelic Practitioners Association Announces Standardized  Psychedelic Medicine Therapy Practices At Launch

Seattle, WA, October 11, 2022 – American Psychedelic Practitioners Association (APPA) has announced the launch of their organization, establishing safe, ethical and accessible psychedelic therapy and specific focus Psychedelic Assisted Therapy (PAT), also known as Psychedelic Assisted Psychotherapy (PAP) which National Library of Medicine states: “A radical innovation is psychedelic-assisted psychotherapy (PAP): professionally supervised use psychedelics part of elaborated psychotherapy programs.”

Launching membership at the 15th Horizons Perspective on Psychedelics Conference from October 13th – October 15th in New York City, APPA will be announcing a call to action for practitioners in and with interest in the space to be founding members.

Gaining fast momentum in clinical trials and scientific research, psychedelic medicine is poised to change mental health protocol by helping alleviate serious issues for those suffering. Studies to date represent a breakthrough in efficacy not seen in decades by the mental health field.

To provide support, education, community and mentorship for the psychedelic community, APPA serves as a trusted resource for practitioners, building consensus around Standards of Care and Standards of Training, not yet seen in this space. Nicole T. Buchanan, PhD, Co-chair and Member of the Board of Directors, notes: “The importance of standardizing practices in this space is critical, and we are grateful we are leading the way with standards as a collective group.”

APPA, led by a diverse group: including psychiatrists, psychologists, therapists, lawyers, professors, researchers, and traditional medicine healers, is dedicated to advocating at the national level for safe, effective, and accessible care for all who can benefit from psychedelic medicine.

[bsa_pro_ad_space id=2]
ADVERTISEMENT

APPA invites practitioners and professionals in the community within and beyond psychology, therapy and mental health to sign up to receive support from APPA and learn the critical evolution of regulations and best practices in how patients are treated in this space.

Members have access to a professional network, mentorship program, events and forums, and founding members will be part of shaping the regulations and infrastructure as these therapies enter the U.S. health system. “We are thrilled and humbled to provide a platform to share with practitioners and psychedelic industry members, and bring standards to this space through community, collaboration, and coordinated advocacy,” said Alex Cardenas, Executive Director of APPA.

As a non-profit, APPA has had successful fundraising efforts to date. They are currently accepting donations from individuals and organizations, towards a $2.5 Million goal.

Those professionals in the psychedelic or healthcare space interested, can sign up for memberships online at: https://www.thepsychedelicassociation.org/

Genuine Lasix Online

About APPA

The American Psychedelic Practitioners Association (APPA) exists to integrate psychedelics into the US healthcare system and ensure safe access for all who can benefit from these treatments. APPA brings together (and celebrates) the diverse voices of our community, while building consensus around the needed infrastructure for the healthcare and economic ecosystems to thrive. This includes establishing, as a community, the range of gold standards of care that can effectively help people feel better and find long lasting relief.  The APPA community will also develop standards of training, and a system of accountability to establish PAT as a reliable therapy, ensuring its safe adoption and application throughout the country. Through ongoing educational resources, events and training, we’re establishing APPA as an inclusive community to share knowledge, clarify, and foster pivotal conversations.

Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Next Post
MindMed Prepares to Raise Up to $100M in Capital

Convergence Partners Invests in Psychedelic CRO Clerkenwell Health

Please login to join discussion

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.